Skip to main content Skip to section navigation Skip to footer
Lexaria Bioscience Corp.Lexaria BioscienceLexaria Bioscience
Lexaria Bioscience Corp.

NASDAQ:LEXX; NASDAQ WARRANT:LEXXW

  • Home
  • About
    • Management
    • Board of Directors
    • Advisors & Consultants
  • Technology
    • Overview
    • Commercial Applications
    • Research
    • Patent Portfolio
  • Licensing Opportunities
  • Investors
Contact

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Presentations
  • Company Info
    • Overview
    • Management Team
    • Contacts
    • 2022 Annual General Meeting
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • SEDAR
  • Legend Removal
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
Feb 13, 2020 6:20am EST

Industry Solutions from Lexaria’s DehydraTECHTM Hemp and Cannabis Powders

Jan 22, 2020 6:30am EST

Lexaria Bioscience Corp. and Cannadips Cannabis Announce Expanded Relationship Into Cannabis Oral Pouch & Dip Category

Jan 14, 2020 6:30am EST

Lexaria Bioscience Corp. and Cannadips CBD Announce Definitive Technology Licensing agreement for CBD Oral Pouch & Dip Category

Jan 09, 2020 1:50pm EST

Lexaria Provides Strategic Update from CEO

Nov 21, 2019 6:15am EST

Lexaria’s Technology Now Works in Less Than 10 Minutes

Nov 05, 2019 6:15am EST

Lexaria Bioscience Appoints Gregg Smith as Senior Advisor

Oct 24, 2019 6:15am EDT

Lexaria Applauds FDA Decision on Reduced Risk Tobacco Format

Oct 08, 2019 6:15am EDT

Lexaria Bioscience Provides Update on R&D Program Progress under License Agreement with Altria

Sep 17, 2019 6:15am EDT

Peer Reviewed Clinical Journal Publishes Lexaria Bioscience's Human CBD Study Results

Sep 06, 2019 8:30am EDT

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Featured in NetworkNewsAudio Publication Discussing Innovative Drug-Delivery Discovery

  • Previous Pagearrow_back
  • Page 1
  • …
  • Page 8
  • Page 9
  • Page 10
  • Page 11
  • Page 12
  • Page 13
  • Page 14
  • Page 15
  • Page 16
  • Page 17
  • …
  • Page 20
  • Next Pagearrow_forward
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
Lexaria Bioscience Corp. (NASDAQ:LEXX) has developed and out-licenses its disruptive and cost-effective DehydraTECH™ technology that promotes healthier administration methods, lower overall dosing and higher effectiveness of ingestible drugs and other beneficial molecules.

250.765.6424
info@lexariabioscience.com

Lexaria Bioscience Corp.
#100-740 McCurdy Road
Kelowna, BC, V1X2P7

Privacy Policy

General Disclaimer:
No statement in this web site has been evaluated by the Food and Drug Administration (FDA). Furthermore, none of the statements in this web site should be construed as dispensing medical advice or making claims regarding the cure of diseases…

Read More

Copyright ©2023 All rights reserved.

Back to the top